Evidence map›Paper›PMID 42179890›Full record

ArticleCancer communications (London, England)2026

Sex Impacts Progression-Free Survival of Alectinib through Drug Exposure in Patients with

Daan A C Lanser, Niels Heersche, M Benthe Muntinghe-Wagenaar, Ma Ida Mohmaed Ali, Ezgi B Ulas, Evert de Jonge, Esther Oomen-de Hoop, Marthe S Paats, Idris Bahce, Sander Croes and 8 more

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer communications (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Daan A C LanserDepartment of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, Zuid-Holland, the Netherlands.ORCID https://orcid.org/0009-0006-7827-939X
Niels HeerscheDepartment of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, Zuid-Holland, the Netherlands.ORCID https://orcid.org/0000-0003-2913-8989
M Benthe Muntinghe-WagenaarDepartment of Pulmonary Medicine, University of Groningen, University Medical Center Groningen, Groningen, Groningen, the Netherlands.ORCID https://orcid.org/0000-0003-3785-7406
Ma Ida Mohmaed AliDepartment of Pharmacy and Pharmacology, The Netherlands Cancer Institute, Amsterdam, Noord-Holland, the Netherlands.ORCID https://orcid.org/0000-0002-6853-6763
Ezgi B UlasDepartment of Pulmonary Medicine, Amsterdam University Medical Center, Amsterdam, Noord-Holland, the Netherlands.ORCID https://orcid.org/0000-0003-1551-738X
Evert de JongeDepartment of Clinical Chemistry, Erasmus University Medical Center, Rotterdam, Zuid-Holland, the Netherlands.ORCID https://orcid.org/0000-0002-5775-6488
Esther Oomen-de HoopDepartment of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, Zuid-Holland, the Netherlands.ORCID https://orcid.org/0000-0003-2506-3852
Marthe S PaatsDepartment of Pulmonary Medicine, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, Zuid-Holland, the Netherlands.ORCID https://orcid.org/0000-0003-1602-6195
Idris BahceDepartment of Pulmonary Medicine, Amsterdam University Medical Center, Amsterdam, Noord-Holland, the Netherlands.ORCID https://orcid.org/0000-0002-1111-608X
Sander CroesDepartment of Clinical Pharmacy & Toxicology, Maastricht University Medical Center, Cardiovascular Research Institute Maastricht, Maastricht, Limburg, the Netherlands.ORCID https://orcid.org/0009-0003-5799-1415
Adrianus J LangenDepartment of Thoracic Oncology, The Netherlands Cancer Institute, Amsterdam, Noord-Holland, the Netherlands.ORCID https://orcid.org/0000-0001-7343-633X
Lizza E L HendriksDepartment of Pulmonary Medicine, Maastricht University Medical Center, Research Institute for Oncology and Reproduction, Maastricht, Limburg, the Netherlands.ORCID https://orcid.org/0000-0002-3521-2535
Anthonie J WekkenDepartment of Pulmonary Medicine, University of Groningen, University Medical Center Groningen, Groningen, Groningen, the Netherlands.ORCID https://orcid.org/0000-0001-7175-0026
Alwin D R HuitemaDepartment of Pharmacy and Pharmacology, The Netherlands Cancer Institute, Amsterdam, Noord-Holland, the Netherlands.ORCID https://orcid.org/0000-0003-1939-4639
Ron H N SchaikDepartment of Clinical Chemistry, Erasmus University Medical Center, Rotterdam, Zuid-Holland, the Netherlands.ORCID https://orcid.org/0000-0003-1864-2151
Anne-Marie C DingemansDepartment of Pulmonary Medicine, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, Zuid-Holland, the Netherlands.ORCID https://orcid.org/0000-0001-6105-182X
G D Marijn VeermanDepartment of Pulmonary Medicine, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, Zuid-Holland, the Netherlands.ORCID https://orcid.org/0000-0002-4594-3374
Ron H J MathijssenDepartment of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, Zuid-Holland, the Netherlands.ORCID https://orcid.org/0000-0001-5667-5697

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID42179890
PMCPMC13191087

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.